Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | GPR3 | P46089 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.36 |
| ▸ | GABRE | P78334 | 1/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.36 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.36 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.36 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1486425 | 0.86 | KDM4E (0.41) | KDM4EGPR3PDPK1HPGDHSD17B10 | |
| SCHEMBL2707342 | 0.86 | KDM4E (0.36) | KDM4EGPR3PDPK1GABRPGABRD | |
| SCHEMBL2708519 | 0.83 | ALDH1A1 (0.38) | KDM4EGPR3PDPK1FGFR1MPO | |
| SCHEMBL2709405 | 0.83 | ATM (0.38) | KDM4EGPR3MPOHSD17B10GAA | |
| SCHEMBL10727388 | 0.81 | ERN1 (0.41) | KDM4EGPR3HPGDHSD17B10USP5 | |
| SCHEMBL10727242 | 0.80 | USP5 (0.39) | POLBUSP5GAAPKMNPC1 | |
| Water SCHEMBL10738929 | 0.80 | ERN1 (0.40) | KDM4EGPR3HPGDHSD17B10USP5 | |
| Water SCHEMBL10742458 | 0.79 | USP5 (0.38) | POLBUSP5GAAPKMNPC1 | |
| SCHEMBL5528658 | 0.77 | KDM4E (0.42) | KDM4EGPR3HPGDHSD17B10USP5 | |
| SCHEMBL311098 | 0.77 | PDE5A (0.40) | KDM4EGPR3POLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1789042-B1 | 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2012-05-02 | — | — | EP | disclosed |
| US-7579359-B2 | 1-alkoxy 1H-imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| EP-1789042-A4 | 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20090005376-A1 | imidazonaphthyridines, imidazopyridines, imidazoquinolines, and imidazote-trahydroquinolines; immunomodulators for inducing cytokine biosynthesis; for treatment of viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY | 2009-01-01 | — | — | US | disclosed |
| EP-1789042-A2 | 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006028962-A2 | 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005376-A1 | imidazonaphthyridines, imidazopyridines, imidazoquinolines, and imidazote-trahydroquinolines; immunomodulators for inducing cytokine biosynthesis; for treatment of viral and neoplastic diseases | IL2, IL4, IRF3 | KDM4E 2441/4885GPR3 1280/4885PDPK1 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.